Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.64 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | GPX4 | P36969 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | YAP1 | P46937 | 3/20 | 0.43 |
| ▸ | TEAD4 | Q15561 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9279972 | 1.00 | ALDH1A1 (0.64) | ALDH1A1HTTSMN1; SMN2POLBGPX4 | |
| SCHEMBL11844730 | 1.00 | — | — | |
| SCHEMBL1445091 | 0.89 | ALDH1A1 (0.55) | ALDH1A1HTTSMN1; SMN2POLBGPX4 | |
| SCHEMBL69354 | 0.88 | — | — | |
| SCHEMBL224023 | 0.88 | — | — | |
| SCHEMBL23643793 | 0.87 | ALDH1A1 (0.53) | ALDH1A1HTTSMN1; SMN2POLBGPX4 | |
| SCHEMBL318820 | 0.87 | ALDH1A1 (0.59) | ALDH1A1HTTSMN1; SMN2POLBGPX4 | |
| SCHEMBL23194425 | 0.87 | ALDH1A1 (0.64) | ALDH1A1HTTSMN1; SMN2POLBGPX4 | |
| SCHEMBL5693136 | 0.87 | ALDH1A1 (0.59) | ALDH1A1HTTSMN1; SMN2POLBGPX4 | |
| SCHEMBL31510785 | 0.87 | ALDH1A1 (0.53) | ALDH1A1HTTSMN1; SMN2POLBGPX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025046146-A1 | POLYPEPTIDE SCREENING | Bicycle TX Limited (GB) | 2025-03-06 | — | — | WO | claimed |
| US-20250064950-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | BICYCLETX LIMITED (GB) | 2025-02-27 | — | — | US | claimed |
| US-12150998-B2 | Bicyclic peptide ligands specific for P-selectin | BICYCLETX LIMITED (GB) | 2024-11-26 | — | — | US | claimed |
| EP-4326743-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | BicycleTX Limited (GB) | 2024-02-28 | — | — | EP | claimed |
| WO-2022223969-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | BICYCLETX LIMITED (GB) | 2022-10-27 | — | — | WO | claimed |
| US-20220339289-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | BICYCLETX LIMITED (GB) | 2022-10-27 | — | — | US | claimed |
| EP-4595982-A1 | MONOCONJUGATES AND THEIR PROCESS OF PREPARATION | Syndivia (FR) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025046146-A1 | POLYPEPTIDE SCREENING | Bicycle TX Limited (GB) | 2025-03-06 | — | — | WO | disclosed |
| US-20250064950-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | BICYCLETX LIMITED (GB) | 2025-02-27 | — | — | US | disclosed |
| US-12150998-B2 | Bicyclic peptide ligands specific for P-selectin | BICYCLETX LIMITED (GB) | 2024-11-26 | — | — | US | disclosed |
| WO-2024177503-A1 | STABILIZED NATIVE PROTEIN COMPLEXES CONJUGATED WITH BRANCHED MOLECULES | STICHTING VU (NL) | 2024-08-29 | — | — | WO | disclosed |
| EP-4326743-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | BicycleTX Limited (GB) | 2024-02-28 | — | — | EP | disclosed |
| US-20240018508-A1 | PHAGE CYCLISATION ASSAY | Bicyclerd Limited (GB) | 2024-01-18 | — | — | US | disclosed |
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2020-12-08 | — | — | US | disclosed |
| EP-3615550-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BicycleTx Limited (GB) | 2020-03-04 | — | — | EP | disclosed |
| WO-2018197893-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2018-11-01 | — | — | WO | disclosed |
| US-20180311300-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2018-11-01 | — | — | US | disclosed |
| EP-0707572-A1 | IODINATED OLIGOMERIC COMPOUNDS AND DIAGNOSTIC COMPOSITIONS CONTAINING THE SAME | BRACCO S.p.A. (IT) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001966-A1 | IODINATED OLIGOMERIC COMPOUNDS AND DIAGNOSTIC COMPOSITIONS CONTAINING THE SAME | BRACCO S.P.A. (IT) | 1995-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10857196-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | ALDH1A1 4861/4885HTT 1692/4885SMN1; SMN2 4460/4885 |
| US-20180311300-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | ALDH1A1 4861/4885HTT 1692/4885SMN1; SMN2 4460/4885 |
| US-12150998-B2 | Bicyclic peptide ligands specific for P-selectin | SELP, SELPLG, SELE | ALDH1A1 3529/4885HTT 878/4885SMN1; SMN2 1622/4885 |
| US-20220339289-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | SELP, SELPLG, SELE | ALDH1A1 3529/4885HTT 878/4885SMN1; SMN2 1622/4885 |
| US-20250064950-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR P-SELECTIN | SELP, SELPLG, SELE | ALDH1A1 3529/4885HTT 878/4885SMN1; SMN2 1622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.